| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0166-6851(91)90127-R |
| P698 | PubMed publication ID | 1775158 |
| P50 | author | Anthony A Holder | Q46474398 |
| P2093 | author name string | I T Ling | |
| M J Blackman | |||
| S C Nicholls | |||
| P433 | issue | 1 | |
| P921 | main subject | proteolysis | Q33123 |
| Plasmodium falciparum | Q311383 | ||
| P304 | page(s) | 29-33 | |
| P577 | publication date | 1991-11-01 | |
| P1433 | published in | Molecular and Biochemical Parasitology | Q15752756 |
| P1476 | title | Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains | |
| P478 | volume | 49 |
| Q40872637 | A conserved region of the MSP-1 surface protein of Plasmodium falciparum contains a recognition sequence for erythrocyte spectrin |
| Q33599911 | A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. |
| Q35546112 | Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria |
| Q45760438 | Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus |
| Q33290851 | Adhesion molecules and other secreted host-interaction determinants in Apicomplexa: insights from comparative genomics |
| Q34145333 | Advances and challenges in malaria vaccine development. |
| Q37419309 | Allele-specific antibodies to Plasmodium vivax merozoite surface protein-1: prevalence and inverse relationship to haemoglobin levels during infection. |
| Q41887879 | Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites |
| Q39598711 | An additional primary proteolytic processing site merozoite surface protein-1 of Plasmodium berghei |
| Q34334187 | Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum |
| Q55426170 | Anti-band 3 and anti-spectrin antibodies are increased in Plasmodium vivax infection and are associated with anemia. |
| Q36380869 | Antibodies that Inhibit Malaria Merozoite Surface Protein–1 Processing and Erythrocyte Invasion Are Blocked by Naturally Acquired Human Antibodies |
| Q35010158 | Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines |
| Q36800846 | Antibody responses to the merozoite surface protein-1 complex in cerebral malaria patients in India |
| Q30945315 | Antibody-dependent transplacental transfer of malaria blood-stage antigen using a human ex vivo placental perfusion model |
| Q47856744 | Antigenic and sequence diversity at the C-terminus of the merozoite surface protein-1 from rodent malaria isolates, and the binding of protective monoclonal antibodies |
| Q36396844 | Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2. |
| Q48035058 | Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development |
| Q37175084 | Antimalarial activity of cupredoxins: the interaction of Plasmodium merozoite surface protein 119 (MSP119) and rusticyanin |
| Q34999470 | Aotus monkeys: their great value for anti-malaria vaccines and drug testing |
| Q34940333 | Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. |
| Q43939727 | CD36 c.1264 T>G Null Mutation Impairs Acquisition of IgG Antibodies to Plasmodium falciparum MSP1‐19 Antigen and is Associated with Higher Malaria Incidences in Tanzanian Children |
| Q30043019 | Characterisation of PfRON6, a Plasmodium falciparum rhoptry neck protein with a novel cysteine-rich domain |
| Q56451852 | Characterization of C-terminal merozoite surface protein-1 baculovirus recombinant proteins from Plasmodium vivax and Plasmodium cynomolgi as recognized by the natural anti-parasite immune response |
| Q33755404 | Characterization of Protective Epitopes in a Highly Conserved Plasmodium falciparum Antigenic Protein Containing Repeats of Acidic and Basic Residues |
| Q27972927 | Characterization of a conserved rhoptry-associated leucine zipper-like protein in the malaria parasite Plasmodium falciparum |
| Q35551944 | Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds |
| Q30039257 | Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum |
| Q35194707 | Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran |
| Q35551948 | Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii |
| Q37251198 | Conservation and diversification of the transcriptomes of adult Paragonimus westermani and P. skrjabini |
| Q33499694 | Construction of transgenic Plasmodium berghei as a model for evaluation of blood-stage vaccine candidate of Plasmodium falciparum chimeric protein 2.9. |
| Q35550770 | CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine |
| Q27641117 | Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate |
| Q36238733 | DNA vaccines against tropical parasitic diseases |
| Q30042482 | Deletion of the Plasmodium falciparum merozoite surface protein 7 gene impairs parasite invasion of erythrocytes |
| Q44438134 | Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine |
| Q40715913 | Developments with anti-malarial vaccines. |
| Q47874912 | Differences in epitope recognition, isotype and titer of antisera to Plasmodium falciparum merozoite surface protein 4 raised by different modes of DNA or protein immunization |
| Q47846563 | Different Plasmodium falciparum recombinant MSP1(19) antigens differ in their capacities to stimulate in vitro peripheral blood T lymphocytes in individuals from various endemic areas |
| Q34006785 | Different regions of the malaria merozoite surface protein 1 of Plasmodium chabaudi elicit distinct T-cell and antibody isotype responses |
| Q33788247 | Distinct Th1- and Th2-Type prenatal cytokine responses to Plasmodium falciparum erythrocyte invasion ligands |
| Q37597218 | Diversity and population structure of Plasmodium falciparum in Thailand based on the spatial and temporal haplotype patterns of the C-terminal 19-kDa domain of merozoite surface protein-1 |
| Q34006332 | Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial |
| Q47999588 | Epitopes in the 19kDa fragment of the Plasmodium falciparum major merozoite surface protein-1 (PfMSP-1(19)) recognized by human antibodies |
| Q41985489 | Evaluation of recombinant Plasmodium knowlesi merozoite surface protein-1(33) for detection of human malaria |
| Q47917346 | Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. |
| Q30615309 | Expression of deuterium-isotope-labelled protein in the yeast pichia pastoris for NMR studies |
| Q38288459 | Expression of recombinant Plasmodium falciparum subtilisin-like protease-1 in insect cells. Characterization, comparison with the parasite protease, and homology modeling |
| Q48064907 | Expression, purification and characterization of allelic variants of MSP-1(42) from Indian Plasmodium falciparum isolates |
| Q37737126 | Family members stick together: multi-protein complexes of malaria parasites |
| Q94460481 | Gene expression and genetic control to cold tolerance during maize seed germination |
| Q28748331 | Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate |
| Q59792668 | Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 (MSP-1) among Plasmodium knowlesi samples from Malaysia |
| Q36368017 | Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 among Plasmodium vivax Korean isolates |
| Q33847600 | Genome-wide identification of molecular mimicry candidates in parasites |
| Q47895549 | High-Level Production and Purification of P30P2MSP119, an Important Vaccine Antigen for Malaria, Expressed in the Methylotropic Yeast Pichia pastoris |
| Q30409373 | Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice |
| Q47845842 | Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro |
| Q39324003 | Identification and characterization of the merozoite surface protein 1 (msp1) gene in a host-generalist avian malaria parasite, Plasmodium relictum (lineages SGS1 and GRW4) with the use of blood transcriptome |
| Q48004892 | IgG isotype to C-terminal 19 kDa of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil |
| Q34842236 | Immunity to asexual blood stage malaria and vaccine approaches |
| Q34975629 | Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity |
| Q48037488 | Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. |
| Q35516848 | Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection |
| Q35557454 | Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge |
| Q37425845 | Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142). |
| Q34234390 | Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis |
| Q39655089 | In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system |
| Q36005592 | Integration of Multiplex Bead Assays for Parasitic Diseases into a National, Population-Based Serosurvey of Women 15-39 Years of Age in Cambodia |
| Q33880777 | Isolation and characterization of the MSP1 genes from Plasmodium malariae and Plasmodium ovale |
| Q41587442 | Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10. |
| Q34109788 | Juxtamembrane shedding of Plasmodium falciparum AMA1 is sequence independent and essential, and helps evade invasion-inhibitory antibodies |
| Q47895561 | Limited recombination events in merozoite surface protein-1 alleles of Plasmodium falciparum on islands |
| Q34003924 | Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19). |
| Q40592413 | Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity |
| Q47862670 | MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking |
| Q40847091 | Malaria vaccine: roadblocks and possible solutions |
| Q47850948 | Maturation and specificity of Plasmodium falciparum subtilisin-like protease-1, a malaria merozoite subtilisin-like serine protease |
| Q43013555 | Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys |
| Q47827190 | Merozoite surface protein-1 epitopes recognized by antibodies that inhibit Plasmodium falciparum merozoite dispersal. |
| Q34167780 | Mix and match modules: structure and function of microneme proteins in apicomplexan parasites. |
| Q40641469 | Molecular mimicry. |
| Q27972789 | Multiple Plasmodium falciparum Merozoite Surface Protein 1 Complexes Mediate Merozoite Binding to Human Erythrocytes |
| Q35505807 | Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. |
| Q47871031 | Naturally acquired IgM antibody response to the C-terminal region of the merozoite surface protein 1 of Plasmodium vivax in Korea: use for serodiagnosis of vivax malaria. |
| Q44937152 | Naturally acquired antibodies to merozoite surface protein (MSP)-1(19) and cumulative exposure to Plasmodium falciparum and Plasmodium vivax in remote populations of the Amazon Basin of Brazil. |
| Q33998800 | Naturally acquired antibody responses to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in Korea |
| Q34541366 | Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro |
| Q38065630 | New approaches to studying Plasmodium falciparum merozoite invasion and insights into invasion biology |
| Q34154429 | Non-variant specific antibody responses to the C-terminal region of merozoite surface protein-1 of Plasmodium falciparum (PfMSP-119) in Iranians exposed to unstable malaria transmission |
| Q41955368 | Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19). |
| Q34000050 | Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant |
| Q33759208 | Passive Immunization with Antibodies against Three Distinct Epitopes onPlasmodium yoeliiMerozoite Surface Protein 1 Suppresses Parasitemia |
| Q27974391 | Plasmodium cysteine repeat modular proteins 1-4: complex proteins with roles throughout the malaria parasite life cycle |
| Q37116453 | Plasmodium falciparum merozoite surface protein 6 is a dimorphic antigen |
| Q39831592 | Plasmodium falciparum- and merozoite surface protein 1-specific antibody isotype balance in immune Senegalese adults |
| Q31955934 | Plasmodium yoelii YM MAEBL protein is coexpressed and colocalizes with rhoptry proteins. |
| Q34298686 | Potential immune mechanisms associated with anemia in Plasmodium vivax malaria: a puzzling question |
| Q35464579 | Primary structure of the variable region of monoclonal antibody 2B10, capable of inducing anti-idiotypic antibodies that recognize the C-terminal region of MSA-1 of Plasmodium falciparum. |
| Q37681016 | Probiotics: multifarious oral vaccine against infectious traumas |
| Q33356029 | Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses |
| Q42415030 | Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection |
| Q40701948 | Proteins on the surface of the malaria parasite and cell invasion |
| Q34081745 | Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans |
| Q36404193 | Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Secreting Merozoite Surface Protein 1 (MSP1) Induces Protection against Rodent Malaria Parasite Infection Depending on MSP1-stimulated Interferon γ and Parasite-specific Antibodies |
| Q38696399 | Red cell receptors as access points for malaria infection |
| Q28742239 | Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HTTM and Montanide ISA 51 in rhesus macaques |
| Q44142452 | Selection and genetic drift of polymorphisms within the merozoite surface protein-1 gene of Plasmodium falciparum. |
| Q47099079 | Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya |
| Q35383761 | Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum |
| Q47866590 | Spatial and temporal dynamics of the secretory pathway during differentiation of the Plasmodium yoelii schizont |
| Q43144803 | Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant |
| Q33866986 | Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum |
| Q27640198 | Structure of the C-terminal domains of merozoite surface protein-1 from Plasmodium knowlesi reveals a novel histidine binding site |
| Q33711883 | Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii. |
| Q28740432 | T Cell Epitope Regions of the P. falciparum MSP1-33 Critically Influence Immune Responses and In Vitro Efficacy of MSP1-42 Vaccines |
| Q89516787 | The Blood Stage Antigen RBP2-P1 of Plasmodium vivax Binds Reticulocytes and Is a Target of Naturally Acquired Immunity |
| Q40957107 | The Plasmodium falciparum blood stages acquire factor H family proteins to evade destruction by human complement |
| Q37559892 | The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. |
| Q33558061 | The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites |
| Q47998652 | The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite |
| Q39104551 | The complete sequence of Plasmodium berghei merozoite surface protein-1 and its inter- and intra-species variability |
| Q27618095 | The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate |
| Q37471465 | The future for blood-stage vaccines against malaria |
| Q40826489 | The microneme protein MIC3 of Toxoplasma gondii is a secretory adhesin that binds to both the surface of the host cells and the surface of the parasite |
| Q37522784 | The presence of T cell epitopes is important for induction of antibody responses against antigens directed to DEC205+ dendritic cells |
| Q39341380 | The red cell membrane and invasion by malarial parasites. |
| Q34572160 | Towards a blood-stage vaccine for malaria: are we following all the leads? |
| Q34003578 | Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys |
Search more.